Free Trial
NASDAQ:NXTC

NextCure Q1 2024 Earnings Report

NextCure logo
$0.50 -0.01 (-1.26%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NextCure EPS Results

Actual EPS
-$0.61
Consensus EPS
-$0.45
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

NextCure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NextCure Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 2, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

NextCure's Q2 2025 earnings is scheduled for Thursday, August 7, 2025, with a conference call scheduled on Friday, August 1, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

NextCure Earnings Headlines

The Secret Map of America, Declassified…
Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “secret America” — an America first envisioned by President Harry Truman in 1946, and then classified by the government for decades.
Piper Sandler Sticks to Its Buy Rating for NextCure (NXTC)
See More NextCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NextCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextCure and other key companies, straight to your email.

About NextCure

NextCure (NASDAQ:NXTC), a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

View NextCure Profile

More Earnings Resources from MarketBeat